Molecular Vision Strengthens IP Portfolio
Molecular Vision, a developer of quantitative point-of-care diagnostic devices, announces that it has further strengthened its IP position around its proprietary technology platform, BioLEDTM. BioLEDTM is a miniaturised, low-cost, lab-quality easy to use point-of-care device, which can simultaneously test multiple samples using an optical detection technology to measure the light signal change associated with one or several optical parameters in biological assays.
The Company has received notification from The United States Patent and Trademark Office that it has been given notice of allowance for grant of a patent for a method of patterning a thin film, which is licensed from Imperial Innovations plc. The patent covers a method for patterning thin films in organic semiconductor devices, as required for the low-cost fabrication of Organic Light Emitting Diodes (OLEDs) and Organic Photodetectors (OPDs).
Combining OLEDs and OPDs with microfluidic devices underpins the Company’s disruptive technology platform, allowing it to create fully disposable, low-cost medical diagnostic devices that are suitable for home testing.
BioLEDTM is a versatile optical detection platform that has the potential to be used across a wide range of applications where disposable, quantitative, simple to use, on-site analysis is required. These include medical diagnostics for point-of-care testing, in-the-field veterinary testing, food and plant testing, environmental monitoring, and security.
Chris Hand, Chief Executive Officer of Molecular Vision, said: “We are pleased to have further strengthened our IP portfolio around our proprietary platform technology. This will be critical for commercialising our second generation fully disposable medical diagnostic devices. There is a growing need for accurate, low cost, quantitative on-site diagnostic tests and this patent further validates our strong position in this market.”
Enquiries: Molecular Vision / Abingdon Health +44 (0)1865 339490 Dr Chris Hand, Chief Executive Officer Dr Oliver Hofmann, Business Development
Media Enquiries: FTI Consulting Ben Atwell, Natalie Garland-Collins +44 (0)203 727 1000
Notes to editors
Molecular Vision – www.molecularvision.co.uk
Molecular Vision is an optical detection company that has developed a platform technology for versatile and quantitative optical detection in a portable format. Commercialisation efforts are focused on developing medical diagnostic devices for the point-of-care.
Molecular Vision’s BioLEDTM platform measures light signal changes associated with one or more optical parameters in biological assays. To date, Molecular Vision has established the flexibility of the platform by multiplexing an albumin and creatinine panel in a urine sample as well as a Myoglobin, CK-MB and Troponin I panel in a serum sample; each panel respectively, on an integrated microfluidic device.
Molecular Vision’s commercialisation strategy is based on diagnostic product development with parent company Abingdon Health, a specialist medical diagnostics business, and acquisition of third-party development contracts.
Abingdon Health – www.abingdon-health.com
Abingdon Health is a specialist medical diagnostics company based in Oxford with facilities in London, Birmingham and York. The Company works with the world’s best scientists to acquire, develop and distribute state-of-the art diagnostic tools and services. Abingdon’s mission is to create a global, diversified healthcare business through both selective acquisition and the development of patent protected, clinically relevant diagnostic products.
Abingdon was founded in 2008 by CEO Dr Chris Hand, Chris Yates and Dr Brett Pollard, to commercialise a portfolio of novel clinical diagnostics technologies. Chris Hand is the ex co-founder and CEO of Cozart Bioscience Ltd, which sold for £65 million to Concateno plc in 2007. He was then non-executive director of Concateno plc until its subsequent sale to Inverness Medical Innovations (IMA) for £147 million in 2009. Prior to joining Abingdon, Brett Pollard was Head of Life Science Research at Numis and equity analyst at both Seymour-Pierce and Deutsche Bank.
